{"id":17954,"date":"2026-07-10T10:29:23","date_gmt":"2026-07-10T08:29:23","guid":{"rendered":"https:\/\/bbmri.at\/?post_type=news-articles&p=17954"},"modified":"2026-07-14T14:54:50","modified_gmt":"2026-07-14T12:54:50","slug":"psoriasis-registry-austria-psora","status":"publish","type":"news-articles","link":"https:\/\/bbmri.at\/de\/news-articles\/psoriasis-registry-austria-psora\/","title":{"rendered":"Psoriasis Registry Austria (PsoRA)"},"content":{"rendered":"
\n
\n
\n \n

\n Psoriasis Registry Austria (PsoRA) <\/h1>\n \n

\n Eine herausragende interdisziplin\u00e4re Kohorte des BBMRI.at-Partners Medizinische Universit\u00e4t Graz an der Biobank Graz <\/h3>\n \n
\n

Das Psoriasis Registry Austria (PsoRA) wurde 2009 gegr\u00fcndet, um die Behandlung von Psoriasis-Patient in \u00d6sterreich systematisch zu dokumentieren und kontinuierlich zu verbessern. Die von der Medizinischen Universit\u00e4t Graz<\/a> in Zusammenarbeit mit der \u00d6sterreichischen Gesellschaft f\u00fcr Dermatologie und Venerologie (\u00d6GDV)<\/a> entwickelte webbasierte Datenbank ist in das europaweite Psoriasis-Register \u201eInitiative PsoNet\u201c eingebettet.<\/p>\n

 <\/p>\n

PsoRA enth\u00e4lt detaillierte Informationen zur Behandlung von Psoriasis-Patient. \u00dcber viele Jahre hinweg wurden s\u00e4mtliche angewandten Therapieoptionen, deren zeitliche Abfolge, Nebenwirkungen sowie Behandlungserfolge unter den Bedingungen der klinischen Routineversorgung dokumentiert. Gemessen an der Bev\u00f6lkerungsgr\u00f6\u00dfe z\u00e4hlt diese \u00f6sterreichische Datenbank zu den gr\u00f6\u00dften ihrer Art weltweit.<\/p>\n <\/div>\n \n <\/div>\n\n\n\n

<\/div>\n <\/div>\n\n <\/div>\n\n\n
\r\n
\r\n
\r\n

\r\n Profil der Kohorte (auf Englisch) <\/h3>\r\n \r\n \r\n\r\n
\r\n
\r\n

\r\n <\/h4>\r\n

\r\n <\/h4>\r\n <\/div>\r\n\r\n
\r\n
\r\n
\r\n Research Area <\/div>\r\n
\r\n Improve therapy of patients with psoriasis in Austria under everyday conditions
\r\n\u2022 Therapy efficacy in clinical routine
\r\n\u2022 Therapy response
\r\n\u2022 Long-term therapy
\r\n\u2022 Therapy changes and side effects <\/div>\r\n <\/div>\r\n
\r\n
\r\n Cohort Type <\/div>\r\n
\r\n Human, observational, retrospective, cross-sectional <\/div>\r\n <\/div>\r\n
\r\n
\r\n Cohort Size <\/div>\r\n
\r\n \u2022 >2200 samples from >850 patients in >27.000 aliquots, from >350 patients >samples
\r\n\u2022 Collection ongoing <\/div>\r\n <\/div>\r\n
\r\n
\r\n Biological Sample Types (with storage condition) <\/div>\r\n
\r\n \u2022 Serum
\r\n\u2022 EDTA plasma
\r\n\u2022 Buffy coat
\r\n\u2022 PaxGene
\r\n
\r\nStored in Biobank Graz at -80\u00b0C <\/div>\r\n <\/div>\r\n
\r\n
\r\n Associated Data <\/div>\r\n
\r\n Base demographic
\r\nPsoriasis specific disease scores and treatment outcome
\r\nConcomitant medication
\r\nConcomitant diseases
\r\nRoutine haematology results (including organ function ALAT, ASAT, GGT, LDH, CRK, \u2026) <\/div>\r\n <\/div>\r\n
\r\n
\r\n Donors Details <\/div>\r\n
\r\n \u2022 34.7% female : 65.3% male
\r\n\u2022 Median age 46,4 [18 – 82]
\r\n\u2022 Median BMI 27.4 [16.9 \u2013 55.4]
\r\n
\r\nPsoriasis patients scheduled for biologics treatment in Graz, sampled at different time points (na\u00efve, 0-1M, 1-4 M, 4-8M, 8-16M, u003e16M after treatment) <\/div>\r\n <\/div>\r\n
\r\n
\r\n Collection Period <\/div>\r\n
\r\n 2016 – ongoing <\/div>\r\n <\/div>\r\n
\r\n
\r\n Informed Consent <\/div>\r\n
\r\n Broad biobank consent & specific study IC <\/div>\r\n <\/div>\r\n
\r\n
\r\n Access <\/div>\r\n
\r\n Yes – collaboration only <\/div>\r\n <\/div>\r\n
\r\n
\r\n Quality Standards <\/div>\r\n
\r\n ISO 9001:2015 (Biobank Graz) for serum, EDTA sample aliquots <\/div>\r\n <\/div>\r\n
\r\n
\r\n Contact <\/div>\r\n
\r\n Principal investigators:
\r\n\u2022 Prof. Dr. Peter Wolf, peter.wolf@medunigraz.at
\r\n\u2022 Dr. Thomas Graier, thomas.graier@medunigraz.at
\r\n\u2022 Dr. Natalie Bordag, n.bordag@medunigraz.at <\/div>\r\n <\/div>\r\n
\r\n
\r\n Publications (scientific) <\/div>\r\n
\r\n List see below <\/div>\r\n <\/div>\r\n
\r\n
\r\n Media articles <\/div>\r\n
\r\n See below <\/div>\r\n <\/div>\r\n
\r\n
\r\n Research projects <\/div>\r\n
\r\n \u2022 Predictive biomarkers for therapeutic response
\r\n\u2022 Surrogate markers for systemic inflammation and co-morbidities <\/div>\r\n <\/div>\r\n <\/div>\r\n \r\n <\/div>\r\n <\/div>\r\n\r\n
<\/div>\r\n\r\n <\/div>\r\n <\/div>\r\n\n\n
\r\n
\r\n
\r\n \r\n \"\"\r\n <\/span>\r\n <\/a>\r\n <\/div>\r\n
<\/div>\r\n <\/div>\r\n <\/div>\r\n\n\n
\r\n
\r\n
\r\n
\r\n 
Publikationen (wissenschaftlich):\r\n\r\n\r\n<\/pre>\n